Company Filing History:
Years Active: 2009
Title: The Innovative Contributions of Pascal Neuville
Introduction
Pascal Neuville is a notable inventor based in La Wantzenau, France. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic gene expression systems. His work focuses on innovative solutions that enhance the control of gene expression in smooth muscle cells.
Latest Patents
Neuville holds a patent for "Chimeric promoters for controlling expression in smooth muscle cells." This invention involves a chimeric construct that comprises a smooth muscle cell (SMC)-specific promoter operably linked to a muscle-specific enhancer. The patent also includes an expression cassette that utilizes this chimeric construct to regulate the expression of therapeutic genes. Furthermore, it encompasses a recombinant vector, a viral particle, and a eukaryotic host cell, along with a composition that includes the expression cassette. These innovations are aimed at achieving specific expression in SMCs for therapeutic or prophylactic purposes, as well as methods for treating human or animal organisms. Additionally, the invention relates to a transgenic non-human animal that integrates the chimeric construct, expression cassette, or vector into its genome.
Career Highlights
Pascal Neuville is associated with Transgene S.A., a company that specializes in the development of immunotherapies for cancer and infectious diseases. His work at Transgene has been pivotal in advancing the understanding and application of gene therapy techniques.
Collaborations
Neuville has collaborated with notable colleagues such as Sébastien Ribault and Majid Mehtali. These partnerships have contributed to the successful development and implementation of innovative biotechnological solutions.
Conclusion
Pascal Neuville's contributions to biotechnology, particularly through his patent on chimeric promoters, highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in therapeutic gene expression and treatment methodologies.